Value of Sodium Glucose co Transporter 2 Inhibitor Versus Traditional Medication In Microalbuminuric Diabetic Patients

BACKGROUND Sodium glucose co transporter 2 inhibitor (SGLT2i) is a new arment in the prevention and treatment of diabetic kidney disease with a potential effect on reducing and preventing chronic kidney disease (CKD) progression. OBJECTIVE To evaluate the effect of SGLT2 inhibitor in comparison to traditional medication in diabetic patients with microalbuminuria. PATIENTS AND METHODS 60 diabetic patients with microalbuminuria were divided into group I: 30 patients were treated by traditional medications (RAAS blockers) and group II: 30 patients for whom Dapagliflozin was added to the traditional medications. All patients were followed up for 6 months with measuring of urine albumin/creatinine ratio (UACR) and eGFR changes. RESULTS UACR significantly declined after 6 months of treatment in group II with (p-value <0.001). There was no significant eGFR changes between both groups. Systolic blood pressure decreases in both groups but the decrease was highly significant in group II (pvalue<0.001). Diastolic blood pressure decreases significantly in both groups (p-value<0.001). Also, body weight reduced significantly in group II with (p-value<0.001). CONCLUSION Dapagliflozin when added to traditional medications (RAAS Blockers) has resulted in significant reduction in microalbuminuria with no significant eGFR changes.